

OB/GYN CHART REVIEW

A summary of OB/GYN clinical chart review results designed to monitor the quality of care provided by a Ryan White funded OB/GYN primary care site as part of the Atlanta EMA's quality management plan.


*Prepared for Fulton County Government's Ryan White Part A Program
By the Southeast AIDS Training and Education Center
Emory University School of Medicine*

Methodology


- Purpose: To examine the extent to which a Ryan White funded primary care site is providing care that meets quality of care indicators for HIV positive obstetric patients.
- Reviewers: Barbara Blake, RN, PhD, ACRN and
Gloria Taylor, DSN, RN
- Electronic Medical Record System: EPIC
- Completed: April 2013
- Extraction Tool: From baseline Quality of Care Measures used in the development of primary care quality management standards and indicators in the EMA, based on Public Health Service Guidelines and acceptable clinical practices as well as quality indicators for providers of pregnant women with HIV. Susan Richardson, MN, MPH, FNP-BC assisted in the creation and accuracy of the tool.
- Patient Chart Selection: Systematic sampling of 2011 HIV positive obstetric clinic patients
- Total Charts Reviewed: 32

Patient Demographics

Race/Ethnicity



Age




Clinic History and Engagement

Measures

1. Patient meets eligibility criteria
2. Date of initial OB visit (not shown)
3. Patient was new to clinic during study period
4. Date of first IDP visit (not shown)
5. If not IDP, name of HIV provider prior to coming to Grady (not shown)
6. Name of other provider (not shown)
7. Ever IDP visit

Clinic History and Engagement


1. Meets eligibility criteria




Eligibility criteria:

- HIV positive
- Pregnant
- Had at least one medical visit within the review period
- Necessary chart volumes were accessible

3. New to clinic during study period



7. Ever IDP visit



HAB Performance Measures

HAB Group 1: Serve as foundational measures for HIV provision of care	Performance Measure	EMA Indicator Goal
HAB Group 2: Important measures that should seriously be considered for inclusion in HIV clinical care	Prescribed ARV therapy for pregnant women	None available
	Had ≥ 2 CD4 T-Cell Counts within measurement year	90%
	Had ≥ 2 medical visits in an HIV care setting (OB clinic)	85%
	Assessed and Counseled for adherence ≥ 2 times at least three months apart	90%
	Has completed the HBV vaccination series	CDC goal: 45%
	HCV screening was performed at least once since diagnosis of HIV	95%
	Has received HIV risk counseling within the measurement year	85%
	If on ARV therapy, had a fasting lipid panel during measurement year	HIVQUAL 2006 Median: 85%
	Had a test for syphilis performed within the measurement year	90%
	Had a test with documented results for LTBI since HIV diagnosis	100%
HAB Group 3: “Best practice” areas of care that lack written clinical guidelines	Had a test for chlamydia within the measurement year	None available
	Had a test for gonorrhea within the measurement year	None available
	Received influenza vaccination within the measurement year	None available
	Documented pneumococcal vaccine	HIVQUAL 2007 Median: 91%
	Documented Toxoplasma screen since HIV diagnosis	HIVQUAL 2007 Median: 84%

Clinical Assessment


Measures

1. Patient has (ever) been diagnosed with AIDS
2. Patient is currently on ART*
3. Two medical visits (at least 3 months apart)*
4. Patient is not currently on ART, but has a history of ART
5. Patient has prior ART regimens listed
6. Patient has prior history of resistance testing
7. If not resistant, ART regimen included at least NRTI
8. Problem list
9. Allergies documented
10. No known allergies (NKA/NKDA)
11. Patient was diagnosed with an STI during study period
12. Patient used tobacco during study period


*Denotes HAB HIV Performance Measure

Clinical Assessment


1. Ever diagnosed with HIV




2a. Currently on ART*



2b. Not currently on ART, but history of ART




3. Two medical visits (at least 3 months apart)*




*Denotes HAB HIV Performance Measure

Clinical Assessment


5. Prior regimen listed




6a. Prior history of resistance testing



6b. If not resistant, ART regimen includes at least 1 NRTI




7. Problem list




Clinical Assessment

9. Allergies documented




10. No known allergies (NKA/NKDA)**




**Although 25 charts did not have documented allergies as noted in graph #9, only 15 had NKA/NKDA indicated in the chart.

11. Diagnosed with STI during study period



12. Used tobacco during study period



Study Period Documentation


Measures

1. Chlamydia, Gonorrhea, Syphilis Screen*
2. Influenza Vaccination*
3. Adherence counseling at every visit*
4. Risk assessment at every visit
5. Risk reduction counseling at every visit*
6. Hepatitis B co-infection
7. Hepatitis C co-infection
8. Hepatitis B past infection with immunity
9. PPD current*


*Denotes HAB HIV Performance Measure

Study Period Documentation


1. Chlamydia and Gonorrhea screen*




1. Syphilis screen*



2. Received influenza vaccine*




3-5. Adherence counseling, risk assessment, risk reduction at every visit*




*Denotes HAB HIV Performance Measure

Study Period Documentation


6-7. Hep B, Hep C co-infection



8. Hep B past infection with immunity



9. PPD current*



*Denotes HAB HIV Performance Measure

Screens and Tests

Measure Group 1: At any point in time	1. Hepatitis B series*
	2. Pneumococcal vaccination*
Measure Group 2: Since HIV diagnosis	3. Hepatitis C screen*
	4. Hepatitis A screen
	5. Toxoplasmosis screen*
	6. LTBI test (TST or IGRA)*
Measure Group 3: Received during study period or during pregnancy	7. Ultrasound in 1 st trimester
	8. If ART 1 st Trimester, Ultrasound 2 nd Trimester
	9. Glucose tolerance test done at 20-23 wks
	10. Liver enzymes and electrolytes monthly at 28 wks to birth
	11. Strep B (vaginal) screen done at 32-36 wks

*Denotes HAB HIV Performance Measure

Screens and Tests

Measure Group 4:
ART and blood work
during study or
throughout pregnancy

12. If ART naïve, baseline resistance testing

13. If on ART at first visit, regimen documented

14. ART regimen at delivery

15. Nevirapine not begun if CD4>250

16. Baseline CBC and chemistries

17. At least 2 CBCs and chemistries (three months apart)


18. First CBCs and chemistries date (not shown)

19. Second CBCs and chemistries date (not shown)

Screens and Test


Measure Group 1: At any point in time

1-2. Hep B vaccination series, pneumococcal vaccination*




Measure Group 2: Since HIV Diagnosis


3. Hep C screen*



4. Hep A screen*



5. Toxoplasmosis screen*




*Denotes HAB HIV Performance Measure


Screens and Test

Measure Group 2: Since HIV Diagnosis

6. LTBI test (TST or IGRA)*




8. If ART during 1st trimester, ultrasound during 2nd trimester




Measure Group 3: Received during study period or pregnancy

7. Ultrasound in 1st trimester



9. Glucose tolerance done at 20-23 weeks




*Denotes HAB HIV Performance Measure


Screens and Tests

Measure Group 3: Received during study period or pregnancy

10. Liver enzymes and electrolytes monthly at 28 wks to birth




11. Strep B (vaginal) screen done at 32-36 weeks



Measure Group 4: ART and blood work during study or throughout pregnancy


12. If ART naïve, baseline resistance testing**




**Only 1 patient had NO history of ART (ART naïve), but 3 were tested of the 32 total charts.

Screens and Tests

13. On ART at first visit




13.1. If on ART at first visit, regimen documented




Screens and Tests


14. ART regimen at delivery



15. Nevirapine not begun if CD4>250




16. Baseline CBC and chemistries



Screens and Tests

17. At least 2 CBC and chemistries (3 months apart)



CD4 and Viral Load


Measures

1. CD4 and viral load at initial visit
2. Two CD4 cell count tests (at least 3 months apart)*
3. If VL >500-1,000 on ART, resistance testing done
4. VL at 34-36 wks for mode of delivery decision
5. VL every three months until birth*
- Only three (9%) charts reviewed indicated having a VL every 3 months until birth
6. VL at first visit
7. VL at delivery


*Denotes HAB HIV Performance Measure

CD4 and Viral Load


1. CD4 and VL at initial visit




2. Two CD4 cell count tests (at least 3 months apart)*



3. If VL > 500-1,000 on ART, resistance testing done



4. VL at 34-36 weeks for mode of delivery decision



*Denotes HAB HIV Performance Measure

Medications

- Nucleoside/Nucleotide Analogue Reverse Transcriptase Inhibitors (NRTI)

HIV Medication	Frequency	Percent
Combivir	19	59.4
Emtriva	31	96.9
Epivir	31	96.9
Epzicom	2	6.3
Hivid	0	-
Retrovir	31	96.9
Trizivir	1	3.1
Truvada	7	21.9
Videx EC	0	-
Videx	0	-
Viread	30	93.8
Zerit	0	-
Ziagen	0	-

Medications

- Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)

HIV Medication	Frequency	Percent
Intelence	1	3.1
Rescriptor	0	-
Sustiva	0	-
Viramune	0	-

- HIV Inhibitors

HIV Medication	Frequency	Percent
Isentress	3	9.4

- Entry Inhibitors

HIV Medication	Frequency	Percent
Selzentry	0	-

Medications

- Fusion Inhibitors

HIV Medication	Frequency	Percent
Fuzeon	0	-

- Multi-Class

HIV Medication	Frequency	Percent
Atripla	0	-

Medications

- Protease Inhibitors (PI)

HIV Medication	Frequency	Percent
Agenerase	0	-
Aptivus	0	-
Crixivan	0	-
Fortovase	0	-
Invirase	0	-
Kaletra	19	59.4
Lexiva	0	-
Norvir	8	25.0
Prezista	2	6.3
Reyataz	6	18.8
Viracept	1	3.1

Limitations and Reviewer Observations

- Only portions of patient charts were made available to reviewers
 - Lab results
 - Sections of chart that were deemed acceptable to respond to pre-submitted questions
- Full delivery record not available
- Observations
 - Population came into care late
 - Some may have been transferred but this information was not made available and was unable to be reviewed
 - One incarcerated patient chart
 - Few appointments recorded across the board considering pregnancy